Bio-Techne Corp (TECH)
NEUTRALFondamentale
53
Prezzo
$72.34
Capitalizzazione
$11.27B
Parte 1 · Quanto vale l'azienda
Panoramica
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Per questa società non c'è ancora una scheda redazionale
Per questa società non c'è ancora un elenco di concorrenti.
Stato Patrimoniale e Liquidità
Ricavi
$1.21B
Ultimi 12 mesi (al 31/03/2026)
Utile Netto
$110M
Ultimi 12 mesi (al 31/03/2026)
Free Cash Flow
$257M
Patrimonio Netto Totale
$1.92B
Passività Totali
$639M
Rapporto di Liquidità
4.49
Copertura Interessi
15.88
Debito/EBITDA
1.37
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$40.41
Prezzo Attuale
$72.34
Margine di Sicurezza
-79.0%
Range Fair Value
$26.27 - $54.55
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
104.91
ROE
3.8%
Rapporto P/B
5.44
P/FCF
42.04
Margine Lordo
65.0%
ROIC
5.1%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
5.1%
WACC
11.4%
ROIC − WACC
-6.4 pp
Il ROIC è sotto il costo del capitale: l'azienda distrugge valore per ogni dollaro investito.
Criteri di Analisi Fondamentale
Superati (15)
- Price CAGR 10.90%
- ROIC 5.1%
- Gross Margin 65.0%
- Debt/Equity ratio
- Operating Margin 12.7%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 10.6%
- Earnings Quality (OCF/NI) 2.69
- Share Dilution -0.3%
- Piotroski F-Score 5/9
Non superati (11)
- EPS shows upward trend
- EPS CAGR -10.63%
- P/FCF 42.04
- P/B Ratio 5.44
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 5.4%
- Analyst Consensus 41% Buy
- Earnings Surprise avg 0.7%
- Net Margin Trend 9.0% vs 10.9%
Non disponibili (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Segnali misti: alcune aree necessitano attenzione
Qualità degli Utili
Alta qualità: utili supportati da cash
Diluizione Azionaria
Riacquisto azioni. Favorevole agli azionisti
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Mr. Kim Kelderman | CEO, President & Director | 57 |
| Mr. William A. Geist | President of Protein Sciences Segment | 56 |
| Dr. Gary J. Latham Ph.D. | VP & CTO | - |
| Mr. David Clair C.F.A. | Vice President of Investor Relations | - |
Rischio Audit
8
Rischio CdA
1
Rischio Compensi
10
Rischio Diritti Azionisti
1
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Ultime Notizie
Ultime notizie per TECH, da Markets Gazette.
- 6/15/2026POSITIVEActivist Investor Ananym Urges Bio-Techne to Consider Selling
Activist investor Ananym Capital Management has acquired a significant stake in Bio-Techne Corp., signaling a potential shift in the company's strategic direction. Ananym is actively urging the Bio-Techne board to initiate a comprehensive strategic review, with a primary focus on exploring a potential sale of the company. This development could lead to a substantial premium for shareholders if a sale materializes, as activist campaigns often aim to unlock shareholder value through such actions. Investors will be closely watching Bio-Techne's response and any subsequent strategic decisions.
- 3/13/2026NEGATIVEIs Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?
A significant wealth management firm has divested its entire stake in Bio-Techne Corporation, a developer of life sciences reagents and diagnostic solutions. While the specific reasons for the liquidation were not disclosed, the complete exit by a major investor raises concerns about potential headwinds or a reassessment of the company's future growth prospects. Investors will be closely watching for any further commentary from the firm or Bio-Techne management to understand the underlying drivers of this substantial sell-off, which could impact short-term sentiment and stock performance.
via Markets Gazette